Page last updated: 2024-12-09
npc 15199
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 1549477 |
| CHEMBL ID | 152028 |
| CHEBI ID | 188600 |
| SCHEMBL ID | 800078 |
| MeSH ID | M0219167 |
Synonyms (77)
| Synonym |
|---|
| 2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methyl-pentanoic acid |
| (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid |
| BRD-K65275554-001-02-1 |
| DIVK1C_001012 |
| KBIO1_001012 |
| SPECTRUM_001482 |
| IDI1_001012 |
| (npc-15199) |
| NCGC00024724-01 |
| tocris-0675 |
| BSPBIO_002789 |
| SPECTRUM5_001340 |
| n-fmoc-d-leucine |
| KBIO2_004530 |
| KBIO2_001962 |
| KBIO2_007098 |
| KBIOGR_000649 |
| KBIO3_002289 |
| KBIOSS_001962 |
| SPBIO_001395 |
| NINDS_001012 |
| SPECTRUM3_001175 |
| SPECTRUM2_001468 |
| SPECTRUM4_000165 |
| SPECTRUM1502083 |
| fmoc-d-leu-oh, >=95.0% (tlc) |
| 114360-54-2 |
| n-[(9h-fluoren-9-ylmethoxy)carbonyl]-d-leucine |
| F0603 |
| fmoc-d-leu-oh |
| CHEMBL152028 , |
| n- (9-fluorenylmethoxycarbonyl)-l-leucine |
| bdbm50121968 |
| HMS503K05 |
| (2r)-2-(9h-luoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid |
| CHEBI:188600 |
| (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methyl-pentanoic acid;fmoc-d-leu-oh |
| A803174 |
| NCGC00024724-02 |
| NCGC00024724-03 |
| fmoc-d-leucine |
| AKOS015924103 |
| CCG-39195 |
| npc-15199 |
| M03366 |
| AM81874 |
| SCHEMBL800078 |
| n-9-fluorenylmethyloxycarbonyl-d-leucine |
| J-300158 |
| (2r)-2-({[(9h-fluoren-9-yl)methoxy]carbonyl}amino)-4-methylpentanoic acid |
| DS-2292 |
| Q-101637 |
| d-leucine, n-[(9h-fluoren-9-ylmethoxy)carbonyl]- |
| npc 15199 |
| FD21857 |
| mfcd00062957 |
| CS-W008021 |
| n-alpha-(9-fluorenylmethyloxycarbonyl)-d-leucine |
| sr-01000597659 |
| SR-01000597659-1 |
| AC-8595 |
| EN300-81304 |
| HMS3675O14 |
| fmoc-dleu |
| n-(9-fluorenylmethoxycarbonyl)-d-leucine |
| CBPJQFCAFFNICX-LJQANCHMSA-N |
| (r)-2-(((9h-fluoren-9-yl)methoxy)carbonylamino)-4-methylpentanoic acid |
| HMS3411O14 |
| BRD-K65275554-001-03-9 |
| (((9h-fluoren-9-yl)methoxy)carbonyl)-d-leucine |
| (r)-2-((((9h-fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanoic acid |
| (2r)-2-{[(9h-fluoren-9-ylmethoxy)carbonyl]-amino}-4-methylpentanoic acid |
| HY-W008021 |
| Z1123720095 |
| 98ZC4255U2 |
| (r)-n-fmoc-leucine |
| PD001396 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| leucine derivative | An amino acid derivative resulting from reaction of leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of leucine by a heteroatom. The definition normally excludes peptides containing leucine residues. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (6)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 15.8489 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 63.0957 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 12.5893 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 7.9433 | 0.0063 | 6.9043 | 39.8107 | AID883 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 7.9433 | 0.0063 | 8.2350 | 39.8107 | AID883 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (29)
Molecular Functions (4)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protein binding | Insulin-like growth factor-binding protein 5 | Homo sapiens (human) |
| insulin-like growth factor I binding | Insulin-like growth factor-binding protein 5 | Homo sapiens (human) |
| fibronectin binding | Insulin-like growth factor-binding protein 5 | Homo sapiens (human) |
| insulin-like growth factor II binding | Insulin-like growth factor-binding protein 5 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (5)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Insulin-like growth factor-binding protein 5 | Homo sapiens (human) |
| endoplasmic reticulum lumen | Insulin-like growth factor-binding protein 5 | Homo sapiens (human) |
| insulin-like growth factor binding protein complex | Insulin-like growth factor-binding protein 5 | Homo sapiens (human) |
| insulin-like growth factor ternary complex | Insulin-like growth factor-binding protein 5 | Homo sapiens (human) |
| extracellular space | Insulin-like growth factor-binding protein 5 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID93218 | Dissociation constant binding to Insulin-like growth factor binding protein 5 at the residue L-81 | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | In silico and NMR identification of inhibitors of the IGF-I and IGF-binding protein-5 interaction. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 13.20
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.20) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||